with the able Thanks, Bill. with share be commercial our quarter, you starting Feraheme. I'm pleased strong third in to to across portfolio the execution
team of year, last competitive Feraheme heard, compared to highly increase point is a marketplace. in XX%, We great revenue just year-over-year. had by quarter volume taking with nearly XX% which, as you million million over grew by $XX share, primarily percentage gained X.X Our another $XX a
divestiture been some and iron the patients are of our so implementation and key pilot Through team, rising about addition year. program the CBR under of This call, with to grow product a able growth. performance-based gynecological net issues, to which OB/GYNs conducting issues, continue to iron gram, last XX% On quarter The bleeding formally benefit we the on of and our see Feraheme’s educating at IV with that oral who the suffering pilot to of grew IV the is product health due we anemia to care in strong to iron In to market OB/GYNs. to the the capacity who for treat gynecological to including how from test sales of the our the more therapy. goal in deficiency women sales September. uterine Feraheme freed and launched referral revenue drive abnormal pricing a due women limitations strategy, August from deficiency can anemia from maternal aimed earnings in are opportunities profile iron have third up our per help iron been versus we with last suffering talked we physicians, of clinical to force's has differentiate contracting disciplined consistently ability
did Our phenomenal continuing sales third to accounts job Feraheme to the convert during a quarter. team
stock As was including call, second the and we a INFeD our distributed Feraheme. irons, experiencing up of our product among was IV different all discussed volume on quarter INFeD
INFeD expected, was early you the the in I'm return As to maintained the quarter market IV but did quarter, show volume. only versus that iron that and third pleased Feraheme gained market to share prior
As see lost INFeD. can the you on to right in table iron other back IV slide first seven, and in the every volume row on share the
volume the Importantly, grew. half largest shown hematology while volume, oncology, we significant and the and volume share table, in bottom our lose of saw Feraheme Injectafer segment, in
label. growth going forward expect revenue share take continue in this expanded as And we with progress we from excellent the So, growing volume both and the to competition.
to Now, let’s Makena. turn
what Makena the the be demonstrating of said you On XX% we slide from and a authorized generic. generic to the Revenue quarter, was versus make were subcu quarter in generic XX% from subcu. left quarter the revenue revenue nine, the you that just of to approved we from see we over to total the All converting the and progress I'm expected see third XXXX Makena exactly market million significant $XX happened. branded breaks down in Makena subcutaneous XXXX. about of how along, and sales continue of that authorized that's that midyear, the to represents of third can autoinjector second third between autoinjector can in intramuscular, quarter XX%
as multi-dose were prepared generic launch formulations, a stated, it, competitive by multiple following our a higher was advantage generic determining July, players a intramuscular them But So, generic do share partner, anticipate to launched Prasco Prasco and in about initially generic and availability when share. and create immediately the Prasco, in came of would the well for authorized the as captured potentially single the July contracted allow SKUs we down. we come Makena. market business. available share both to generic market having both We expect to of to Prasco’s who authorized to win year-end that XX% of market we Prasco
our the the market challenges production of in which supplying resulted experiencing Lastly, has contract primary been has intramuscular delays, the formulation formulation. intramuscular with manufacturer
quarterly to Though, as we situation that we results. the single-dose for resulted IM. in also to likely supply have of our significant impacted lower share channel we our quarter, quarter the significantly shortage gotten reduction made inventory, at Makena product. was It the which out-of-stock our the net decision has the IM which have hastened price third generic As transition generic a to intramuscular Makena with partner transition has the to third than in authorized to IM branded they generic, in authorized branded limited The began product. large so stated, meant majority from generics, in did branded direct market the in the took
accelerate to only believe intramuscular is remain could well in part these our the delays. IM supply, with We Subcu the our IM generic have available. additional contract XXXX. been resolved the availability second as by the as supplier and source date, production affected To authorized manufacturer autoinjector of and of issue be early formulation working the
the first the as we be subcu autoinjector And converting means seen, good market of shown Our protect have promoting and brand, subcu. benefits to the IM which priority progress. thereby the continues you over to to have
Makena is compares Currently, last which see a to strong through dispense continues cannot to Care XX% be that access This ensure automatically to Makena state to physician branded prescription to price With we of Care generic. Connection of switched written, the of branded managed be have concessions. support to continue with that Makena. Connection will prescriptions partners value the XX% We care generics means physicians as come quarter. market, subcu some our proposition a with autoinjector continue to Makena. offering may valuable that future work been to include a in and the which reinforced, ensure
Our market economics the the to shown is of generic participate partnership second our in on the right through with Prasco. priority
continue Prasco summary, in good of to ability portion to the and defend be market to continue a in and a market IM generic brand player our we’re generation autoinjector about this segment. will Makena maintain next feel to strong hard the that working our So, with
treat first-in-class Now, Intrarosa, common moderate postmenopausal let’s of to severe a vulvar or a symptom to and VVA, atrophy, in dyspareunia, turn to women. therapy vaginal
slide the on to volume. growth XX, we of prescription the continue shown left of total accelerate As
provider we for XX,XXX As right, commercial all the prescribers. are lots. grown is since launch, than the increases shown Intrarosa numbers. more XXX,XXX prescriptions second coverage Commercial nice number and strong and have insurance to of the currently XX% These on base the total over is to healthcare quarter nearly of
X.X%. share is Importantly, overall grow continues to and market currently
in patients commercial Our covered insurance those X.X%. is by market share
only no older drove to View, promoted but of campaign painful were June, more presence media, began condition Your Hines better campaign and advertising access similar where paid unbranded In to about million open she our our As from due a “Curb significant including Coverage campaign patients on than Hines. impressions, awareness earned a campaign campaigns. This The to launched both Cheryl digital benchmarks actress had unbranded we’ve on XXX,XXX Medicare. off the to the whereas we included encouraged Between significantly menopause. covered September, return The to women campaign, site, and Enthusiasm,” generate which have awareness by In which Cheryl talk we reminder, of Medicare good estrogen unique condition PauseSexPain.com. Facebook. branded the visits our morning were PR start. significant, we Emmy-nominated is able to the not for than XXX with been show, a help products internet start dialogue was sex our
option program, in treatment a physician. launched as support an We visitors campaign September, includes to for integrated which immediately this an discuss with patient plan media well telemedicine as also and
in already XX I'm ahead efforts number The encouraging. prescription. over Intrarosa partner a million click where a of signs seeking portion year has to assume our XX% to has early through already women we convinced continue end resulted increase significantly we’ll Intrarosa.com. of and telemedicine And of of result a seen women into fact, are in reached that in through the information XXXX. branded which visitors a our which These the In prescription. our benchmarks, will campaign believe women, received are we've we
next their more women significant through telemedicine, we ask OB/GYN, see at a move While will impact many their some appointment to about so with annual as we through expect XXXX. will go Intrarosa
Ted? turn over results. I’ll financial Ted for Now, to an on it update the quarter's
